BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
Company

BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline

Merck & Co. Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China
Company

Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors

InnoCare Pharma's Orelabrutinib Gains NMPA Approval for First-line CLL/SLL Treatment
CompanyDrug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for First-line CLL/SLL Treatment

Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million
CompanyDeals

Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million

Shanghai Junshi Biosciences' Loqtorzi Receives NMPA Approval for Melanoma Treatment
CompanyDrug

Shanghai Junshi Biosciences’ Loqtorzi Receives NMPA Approval for Melanoma Treatment

Innovent Biologics' Aoyixin Wins NMPA Approval for First-line NSCLC Treatment
CompanyDrug

Innovent Biologics’ Aoyixin Wins NMPA Approval for First-line NSCLC Treatment

CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials
CompanyDrug

CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials

Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation
CompanyDeals

Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation

Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)
CompanyDeals

Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)

Digital-Intelligent Transformation of China's Pharmaceutical Industry: 2025-2030 Plan Unveiled
Policy / Regulatory

Digital-Intelligent Transformation of China’s Pharmaceutical Industry: 2025-2030 Plan Unveiled

Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
CompanyDeals

Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development